Home » Newsletters » BioWorld Science

BioWorld Science

June 3, 2021

View Archived Issues

Novel synthetic biotic to promote mucosal healing for treatment of IBD

CIDEC gene silencing ameliorates experimental diabetic cardiomyopathy

Researchers develop new model of extracorporeal membrane oxygenation thrombosis

ADO-09 shown to be superior to insulin aspart in type 1 diabetes patients

ATTR removal observed in vitro and in vivo with NI-006

Encouraging development updates for SupraAntigen-derived liposomal AD vaccine candidates

Centivax enters strategic partnership with NMRC for phase I development of Centi-B9

First patient enrolled in phase Ib study of LB-100 for treatment of small cell lung cancer

Wave Life Sciences presents promising preclinical data for its ADAR editing program

Lophora ApS patents 5-HT2A receptor agonists

Nurix Therapeutics presents new PROTACs

Crinetics Pharmaceuticals synthesizes new melanocortin MC2 receptor antagonists

Merck & Co. identifies nicotinic alpha7 receptor PAMs

Suzhou Zelgen Biosciences synthesizes new GTPase KRAS mutant inhibitors

Phase II results presented from study comparing AZD-9567 versus prednisolone in active RA

Preclinical and early clinical characterization of VIB-7734

Epeleuton shows efficacy in preclinical models of atherosclerosis

New biomarkers identified for diagnosis of Cushing's syndrome

U.K. study identifies another danger of COVID-19: increased antibiotic resistance

Replimune provides updated clinical data for RP-1 and RP-2 programs

Mindset selects its lead next-generation psychedelic candidate, MSP-1014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...